Brief: Surrozen Announces Strategic Partnership With Boehringer Ingelheim To Develop Wnt Agonist Szn-413 For People With Retinal Diseases

Surrozen

06/10/2022 13:00

Oct 6 (Reuters) - Surrozen Inc  SRZN.O :
    * SURROZEN ANNOUNCES STRATEGIC PARTNERSHIP WITH BOEHRINGER
INGELHEIM TO DEVELOP WNT AGONIST SZN-413 FOR PEOPLE WITH RETINAL
DISEASES
    * SURROZEN - BOEHRINGER INGELHEIM  TO GIVE UPFRONT PAYMENT
OF
$12.5 MILLION
    * SURROZEN -  CO WILL ALSO BE ELIGIBLE TO RECEIVE UP TO
$586.5
MILLION IN SUCCESS-BASED DEVELOPMENT, REGULATORY, COMMERCIAL
MILESTONE PAYMENTS
    * SURROZEN - AFTER AN INITIAL PERIOD OF JOINT RESEARCH,
BOEHRINGER
INGELHEIM WILL ASSUME ALL DEVELOPMENT AND COMMERCIAL
RESPONSIBILITIES
    * SURROZEN - BOEHRINGER INGELHEIM WILL RECEIVE AN EXCLUSIVE,
WORLDWIDE LICENSE TO DEVELOP SZN-413 AND OTHER FZD4-SPECIFIC
WNT-MODULATING MOLECULES

Source text for Eikon:  ID: 
Further company coverage:  SRZN.O 
 ((Reuters.Briefs@thomsonreuters.com;))